Microglia are the resident macrophages of the central nervous system (CNS) acting as the
first line of defense in the brain by phagocytosing harmful pathogens and cellular debris …

With the hope that disease-modifying treatments could target the molecular basis of
Parkinson's disease, even before the onset of symptoms, we propose a biologically based …

Background Genome-wide association studies (GWAS) in Parkinson's disease have
increased the scope of biological knowledge about the disease over the past decade. We …

The genetic landscape of Parkinson's disease (PD) is characterised by rare high penetrance
pathogenic variants causing familial disease, genetic risk factor variants driving PD risk in a …

Impaired protein homeostasis and accumulation of damaged or abnormally modified protein
are common disease mechanisms in many neurodegenerative disorders, including …

About 15% of patients with Parkinson disease (PD) have family history and 5–10% have a
monogenic form of the disease with Mendelian inheritance. To date, at least 23 loci and 19 …

Parkinson's disease (PD) is one of the most common neurodegenerative disorders with a
global burden of approximately 6.1 million patients. Alpha-synuclein has been linked to both …

Abstract α-Synuclein (α-Syn) has been extensively studied for its structural and biophysical
properties owing to its pathophysiological role in Parkinson's disease (PD). Lewy bodies …

Abstract Parkinson's disease (PD), the second most common progressive
neurodegenerative disease, develops and progresses for 10–15 years before the clinical …

Gradual degeneration and loss of dopaminergic neurons in the substantia nigra, pars
compacta and subsequent reduction of dopamine levels in striatum are associated with …